Arkolith/Insider Trading/FSTX/Form 4

Bermingham Nessan

DirectorF-star Therapeutics, Inc. (FSTX) · full profile →Form 4 · filed Mar 9, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 8, 2023Tender(U)98K$7.12$695K6K
Mar 8, 2023Disposed to issuer(D)6K$7.12$45K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 8, 2023Disposed to issuer(D)34K——0
Mar 8, 2023Disposed to issuer(D)20K——0
Mar 8, 2023Disposed to issuer(D)20K——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-007657) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML